UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 31

Sortiert nach

A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age

PloS one, 2023-08, Vol.18 (8), p.e0289828-e0289828

2023

Link zum Volltext

Verfügbarkeit prüfen

Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada

American journal of perinatology, 2022-11, Vol.39 (15), p.1668

2022

Link zum Volltext

Verfügbarkeit prüfen

Respiratory Syncytial Virus Prophylaxis in Immunocompromised Children: Outcomes From the Canadian RSV Evaluation Study of Palivizumab Registry Over Twelve Seasons (2005-2017)

The Pediatric infectious disease journal, 2020-06, Vol.39 (6), p.539

2020

Link zum Volltext

Verfügbarkeit prüfen

Respiratory Syncytial Virus Prophylaxis in Neurologic and Muscular Disorders in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab

The Pediatric infectious disease journal, 2019-08, Vol.38 (8), p.775

2019

Link zum Volltext

Verfügbarkeit prüfen

Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants

Journal of medical economics, 2023-12, Vol.26 (1), p.630-643

2023

Link zum Volltext

Verfügbarkeit prüfen

Respiratory syncytial virus hospitalization and incurred morbidities the season after prophylaxis

Paediatrics & child health, 2018-11, Vol.23 (7), p.441-446

2018

Link zum Volltext

Verfügbarkeit prüfen

Respiratory syncytial virus prophylaxis in Down syndrome: a prospective cohort study

Pediatrics (Evanston), 2014-06, Vol.133 (6), p.1031

2014

Link zum Volltext

Verfügbarkeit prüfen

CARESS: The Canadian Registry of Palivizumab

The Pediatric infectious disease journal, 2011-08, Vol.30 (8), p.651-655

2011

Link zum Volltext

Verfügbarkeit prüfen

Respiratory Syncytial Virus in Otherwise Healthy Prematurely Born Infants: A Forgotten Majority

American journal of perinatology, 2018-05, Vol.35 (6), p.541

Paes, Bosco

2018

Link zum Volltext

Verfügbarkeit prüfen

Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention

PloS one, 2015-08, Vol.10 (8), p.e0134711

2015

Link zum Volltext

Verfügbarkeit prüfen

The impact of prophylaxis on paediatric intensive care unit admissions for RSV infection: a retrospective, single-centre study

European journal of pediatrics, 2011-07, Vol.170 (7), p.907-913

2011

Link zum Volltext

Verfügbarkeit prüfen

Exploring respiratory syncytial virus prophylaxis for children with all grades of bronchopulmonary dysplasia

Acta Paediatrica, 2021-01, Vol.110 (1), p.25-27

2021

Link zum Volltext

Verfügbarkeit prüfen

Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab

European journal of clinical microbiology & infectious diseases, 2019-08, Vol.38 (8), p.1561-1568

2019

Link zum Volltext

Verfügbarkeit prüfen

Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?

European journal of clinical microbiology & infectious diseases, 2018-06, Vol.37 (6), p.1113-1118

2018

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy: An International, Prospective Cohort Study

The Pediatric infectious disease journal, 2017-01, Vol.36 (1), p.2-8

2017

Link zum Volltext

Verfügbarkeit prüfen

Value of a risk scoring tool to predict respiratory syncytial virus disease severity and need for hospitalization in term infants

Journal of medical virology, 2015-08, Vol.87 (8), p.1285-1291

2015

Link zum Volltext

Verfügbarkeit prüfen

Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants

Pediatric pulmonology, 2018-05, Vol.53 (5), p.605-612

2018

Link zum Volltext

Verfügbarkeit prüfen

Hospitalization for Respiratory Syncytial Virus Illness in Down Syndrome Following Prophylaxis With Palivizumab

The Pediatric infectious disease journal, 2014-02, Vol.33 (2), p.e29-e33

2014

Link zum Volltext

Verfügbarkeit prüfen

Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada

Current medical research and opinion, 2009-07, Vol.25 (7), p.1585-1591

2009

Link zum Volltext

Verfügbarkeit prüfen

First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005–2015)

European journal of pediatrics, 2017-03, Vol.176 (3), p.413-422

2017

Link zum Volltext

Verfügbarkeit prüfen

72 Use of Palivizumab in Canada; Data from the CARESS registry 2005–2017

Paediatrics & child health, 2019-05, Vol.24 (Supplement_2), p.e28-e28

2019

Link zum Volltext

Verfügbarkeit prüfen

Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease

Infectious diseases and therapy, 2016-12, Vol.5 (4), p.417-452

2016

Link zum Volltext

Verfügbarkeit prüfen

DOES PRESENCE OF DOWN SYNDROME INCREASE RESPIRATORY SYNCYTIAL VIRUS (RSV) RELATED HOSPITALIZATION IN CHILDREN LESS THAN 2 YEARS OF AGE? A SYSTEMATIC REVIEW AND META-ANALYSIS

Paediatrics & child health, 2018-06, Vol.23 (suppl_1), p.e45-e46

2018

Link zum Volltext

Verfügbarkeit prüfen

Respiratory Syncytial Virus Preterm (32-36 Completed Weeks of Gestation) Risk Estimation Measure for RSV Hospitalization in Ireland: A Prospective Study

The Pediatric infectious disease journal, 2016-01, Vol.35 (1), p.19-24

2016

Link zum Volltext

Verfügbarkeit prüfen

Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Congenital Heart Disease

Infectious diseases and therapy, 2017-03, Vol.6 (1), p.37-56

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 31

Suche als RSS-Feed

Aktive Filter

ThemaHospitalization

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(31)

Sprache

Englisch
(31)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(29)
Life Sciences & Biomedicine
(27)
Respiratory Syncytial Virus
(27)
Humans
(25)
Pediatrics
(21)
Infant, Newborn
(20)
Palivizumab
(20)
Female
(18)
Infant
(18)
Male
(18)
Respiratory Syncytial Virus Infections - Prevention & Control
(18)
Risk Factors
(16)
Infectious Diseases
(15)
Gestational Age
(13)
Respiratory Syncytial Virus Infections - Epidemiology
(13)
Antiviral Agents - Therapeutic Use
(11)
Prospective Studies
(11)
Palivizumab - Therapeutic Use
(10)
Prophylaxis
(9)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age

Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada

Respiratory Syncytial Virus Prophylaxis in Immunocompromised Children: Outcomes From the Canadian RSV Evaluation Study of Palivizumab Registry Over Twelve Seasons (2005-2017)

Respiratory Syncytial Virus Prophylaxis in Neurologic and Muscular Disorders in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab

Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants

Respiratory syncytial virus hospitalization and incurred morbidities the season after prophylaxis

Respiratory syncytial virus prophylaxis in Down syndrome: a prospective cohort study

CARESS: The Canadian Registry of Palivizumab

Respiratory Syncytial Virus in Otherwise Healthy Prematurely Born Infants: A Forgotten Majority

Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention

The impact of prophylaxis on paediatric intensive care unit admissions for RSV infection: a retrospective, single-centre study

Exploring respiratory syncytial virus prophylaxis for children with all grades of bronchopulmonary dysplasia

Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab

Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?

Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy: An International, Prospective Cohort Study

Value of a risk scoring tool to predict respiratory syncytial virus disease severity and need for hospitalization in term infants

Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants

Hospitalization for Respiratory Syncytial Virus Illness in Down Syndrome Following Prophylaxis With Palivizumab

Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada

First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005–2015)

72 Use of Palivizumab in Canada; Data from the CARESS registry 2005–2017

Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease

DOES PRESENCE OF DOWN SYNDROME INCREASE RESPIRATORY SYNCYTIAL VIRUS (RSV) RELATED HOSPITALIZATION IN CHILDREN LESS THAN 2 YEARS OF AGE? A SYSTEMATIC REVIEW AND META-ANALYSIS

Respiratory Syncytial Virus Preterm (32-36 Completed Weeks of Gestation) Risk Estimation Measure for RSV Hospitalization in Ireland: A Prospective Study

Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Congenital Heart Disease

Aktive Filter

Suchergebnisse filtern